SLC5A2 and chronic kidney disease: Furthermore, a recent observational prospective cohort study involving 42 CKD patients who initiated SGLT2 inhibitor therapy demonstrated a significant decline in overhydration status that correlated with a decline in both albuminuria and glycosuria over the 6-month trial period [77].